ALLARITY Sponsors $100M SPAC IPO Through Wholly-Owned Subsidiary

The clinical-stage cancer drug developer's Allarity Acquisition Corp. filed an S-1 for a $100 million unit IPO, with Allarity holding about 25% as sponsor.